Results 181 to 190 of about 128,688 (309)

Lack of specificity of antibodies directed against human beta-adrenergic receptors [PDF]

, 2009
Nazha Hamdani, Jolanda van der Velden
openalex   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

A stratified precision medicine trial targeting α_2A-adrenergic receptor agonism as a treatment for the cognitive biotype of depression. [PDF]

Nat Ment Health
Hack LM, Jubeir J, Hilton R, Tozzi L, Boyar L, Zhang X, Lyons T, Jo B, O'Hara R, Schatzberg AF, Williams LM.   +10 more
europepmc   +1 more source

ß-adrenergic receptor blocker poisoning [PDF]

, 2007
Dagmara Ona Reingardienė
openalex   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

Impact of β3-adrenergic receptor agonist on tumor progression and metastasis in renal cell carcinoma models. [PDF]

Cancer Cell Int
Park JS, Lee ME, Jung M, Kim J, Jang WS, Ham WS.   +5 more
europepmc   +1 more source

3,4‐Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50‐kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)‐deficient rats lacking serotonin in the central nervous system

British Journal of Pharmacology, EarlyView.
Background and Purpose 3,4‐Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5‐HT), yet their ...
Tianhua Wang, Rainer K. W. Schwarting, Markus Wöhr   +2 more
wiley   +1 more source

β-adrenergic receptor inhibits heart regeneration by downregulating Yap m6A modification. [PDF]

Cell Death Dis
Guan K, Li Z.
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Genetic inactivation of the β1 adrenergic receptor prevents cerebral cavernous malformations in zebrafish. [PDF]

Elife
Li W, McCurdy S, Lopez-Ramirez MA, Lee HS, Ginsberg MH.   +4 more
europepmc   +1 more source